Nuvation Bio
NUVB · NYSE · United States
Share price · NUVB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NUVB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026-11.4%
- 2 Oct 2026-7.6%
Nothing announced by NUVB that day or the session before.
- 20 Jul 2026+7.9%
- 25 Jun 2026-10.1%
Nothing announced by NUVB that day or the session before.
- 4 Jun 2026+9.5%
Nothing announced by NUVB that day or the session before.
- 3 Jun 2026-3.7%
Nothing announced by NUVB that day or the session before.
- 1 Jun 2026+3.8%
Nothing announced by NUVB that day or the session before.
- 5 May 2026+9.5%
- 3 Mar 2026-25.3%
- 12 Jan 2026-19.7%
Share of unusual movement by asset
For each asset, the share of NUVB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | ROS1Small molecule | Non-Small Cell Lung Cancer ROS1-Positive Non-Small Cell Lung Cancer | |
| Phase 3 | Mutant IDH1Small molecule | Glioma |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
What to watch
2029 (2)
January 2029 (1)
What to watch
May 2029 (1)
What to watch
2030 (2)
August 2030 (1)
What to watch
September 2030 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $45M | $33M | $154M+ $510M short-term inv. | $42M-$39M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $32M | $31M | $259M+ $402M short-term inv. | $63M-$43M operating cash flow | report ↗ |
| 2026-Q1 | $83M | $35M | $125M+ $408M short-term inv. | —$5.1M operating cash flow | report ↗ |
| 2025-Q3 | $13M | $29M | $99M+ $450M short-term inv. | $56M-$53M operating cash flow | report ↗ |
| 2025-Q2 | $4.8M | $27M | $248M+ $360M short-term inv. | $59M-$48M operating cash flow | report ↗ |
| 2025-Q1 | $3.1M | $25M | $48M+ $414M short-term inv. | $53M-$43M operating cash flow | report ↗ |
| 2024-Q3 | $0.7M | $28M | $30M+ $519M short-term inv. | $41M-$31M operating cash flow | report ↗ |
| 2024-Q2 | $1.4M | $29M | $34M+ $543M short-term inv. | $462M-$37M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $13M | $35M+ $562M short-term inv. | $15M-$16M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $19M | $24M+ $595M short-term inv. | $20M-$16M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $19M | $50M+ $581M short-term inv. | $21M-$17M operating cash flow | report ↗ |
| 2023-Q1 | — | $19M | $30M+ $617M short-term inv. | $22M-$19M operating cash flow | report ↗ |
| 2022-Q3 | — | $21M | $139M+ $535M short-term inv. | $27M-$28M operating cash flow | report ↗ |
| 2022-Q2 | — | $29M | $102M+ $601M short-term inv. | $35M-$27M operating cash flow | report ↗ |
| 2022-Q1 | — | $21M | $106M+ $632M short-term inv. | $21M-$25M operating cash flow | report ↗ |
| 2021-Q3 | — | $17M | $345M+ $447M short-term inv. | $22M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $63M | $115M | $164M+ $365M short-term inv. | $51M-$173M operating cash flow | report ↗ |
For fiscal 2025, Nuvation Bio reported revenue of $62.902M, up 699.0% YoY, including $24.663M in net U.S. product revenue from IBTROZI and $38.239M in collaboration and license revenue. R&D expense was $115.106M, up 16.1% YoY. The company ended the period with cash and cash equivalents of $164.086M, and cash, cash equivalents, and marketable securities of $529.2M. Full-year net loss was $204.6M, or $0.60 per share.
Operationally, 216 new patients started IBTROZI in Q4 2025, bringing total new patient starts to 432 since launch in the second half of June 2025, with adoption roughly six times greater than prior recent ROS1 TKI launches based on IQVIA data. The company entered an exclusive license and collaboration agreement with Eisai in January 2026 for taletrectinib in Europe and additional countries outside the U.S., China, and Japan. Positive Phase 2 results for safusidenib in IDH1-mutant glioma showed an ORR of 44% and 88% progression-free at 24 months, and the first patient was enrolled in the pivotal Phase 3 SIGMA trial; Nuvation also received a $25M milestone payment from Nippon Kayaku in Q4.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $7.9M | $99M | $36M+ $467M short-term inv. | $142M-$130M operating cash flow | report ↗ |
| 2023-FY | — | $71M | $43M+ $569M short-term inv. | $19M-$68M operating cash flow | report ↗ |
| 2022-FY | — | $88M | $101M+ $560M short-term inv. | $26M-$96M operating cash flow | report ↗ |
| 2021-FY | — | $69M | $132M+ $633M short-term inv. | $22M-$68M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($118K), 10 sales ($4.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary · CHIEF SCIENTIFIC OFFICER | Option exercise | 100,000 | $1.87 | $187K | Form 4 |
| 2026-08-19 | Hattersley Gary · CHIEF SCIENTIFIC OFFICER | Open-market sale | 100,000 | $7.09 | $709K | Form 4 |
| 2026-08-19 | Hattersley Gary · CHIEF SCIENTIFIC OFFICER | Option exercise (derivative) | 100,000 | — | — | Form 4 |
| 2026-07-15 | Sauvage Philippe · Chief Financial Officer | Option exercise | 39,999 | $2.17 | $87K | Form 4 |
| 2026-07-15 | Sauvage Philippe · Chief Financial Officer | Option exercise | 1 | $1.97 | $2 | Form 4 |
| 2026-07-15 | Sauvage Philippe · Chief Financial Officer | Option exercise (derivative) | 39,999 | — | — | Form 4 |
| 2026-07-15 | Sauvage Philippe · Chief Financial Officer | Option exercise (derivative) | 1 | — | — | Form 4 |
| 2026-06-23 | Sauvage Philippe · Chief Financial Officer | Option exercise | 47,668 | $2.17 | $103K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 230 reporting institutions held 220.3M shares ($907.6M, 62.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 51,989,593 | $223.0M |
| 2 | Decheng Capital LLC | 25,954,439 | $111.3M |
| 3 | BlackRock, Inc. | 25,100,374 | $107.7M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 11,626,198 | $49.9M |
| 5 | Omega Fund Management, LLC | 8,081,089 | $34.7M |
| 6 | Laurion Capital Management LP | 7,822,638 | $33.6M |
| 7 | STATE STREET CORP | 6,784,927 | $29.1M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 5,863,654 | $25.2M |
| 9 | BANK OF AMERICA CORP /DE/ | 3,219,826 | $13.8M |
| 10 | Redmile Group, LLC | 3,153,256 | $13.5M |
| 11 | TANG CAPITAL MANAGEMENT LLC | 3,149,557 | $13.5M |
| 12 | AMERICAN CENTURY COMPANIES INC | 2,897,078 | $12.4M |
| 13 | TWO SIGMA INVESTMENTS, LP | 2,684,089 | $11.5M |
| 14 | Jones Hill Capital LP | 2,383,031 | $10.2M |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,275,446 | $9.8M |